睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients

ClinicalTrials.gov 上登记的一项肺癌开放试验,由南方医科大学南方医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方南方医科大学南方医院Nanfang Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05825443,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. For patients with non-small cell lung cancer who have undergone surgical resection, the TNM stage after surgery is IIA-IIIA;

    入选标准第 2 条

  3. The patient can recover within 3-8 weeks after the operation, and receive postoperative adjuvant treatment;

    入选标准第 5 条

  4. The ECOG PS score is 0 or 1;

    入选标准第 6 条

  5. Absolute neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L, hemoglobin ≥ 9g/dL;

    入选标准第 9 条

    Total bilirubin ≤ 1.5 ULN; AST and ALT ≤ 2.5 ULN;

    入选标准第 10 条

    Serum creatinine ≤ 1.25 ULN, or serum creatinine clearance ≥ 60ml/min;

    入选标准第 11 条

  6. History of HIV infection, active period of HCV infection, active period of HBV infection (HBV-DNA>1000 copies/ml);

    排除标准第 6 条

  7. Female patients must meet: menopause or have undergone surgical sterilization. Women with fertility must take effective contraceptive measures. Do not breastfeed.

    入选标准第 12 条

    During pregnancy or lactation;

    排除标准第 19 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05825443,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Sign the informed consent form before starting the study;
  2. For patients with non-small cell lung cancer who have undergone surgical resection, the TNM stage after surgery is IIA-IIIA;
  3. Patients cannot receive targeted adjuvant therapy;
  4. 18-80 years old;
  5. The patient can recover within 3-8 weeks after the operation, and receive postoperative adjuvant treatment;
  6. The ECOG PS score is 0 or 1;
  7. Have not received any chemotherapy for non-small cell lung cancer before enrollment;
  8. Within 7 days before enrollment, the laboratory inspection must meet all the following requirements:
  9. Absolute neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 100 × 109/L, hemoglobin ≥ 9g/dL;
  10. Total bilirubin ≤ 1.5 ULN; AST and ALT ≤ 2.5 ULN;
  11. Serum creatinine ≤ 1.25 ULN, or serum creatinine clearance ≥ 60ml/min;
  12. Female patients must meet: menopause or have undergone surgical sterilization. Women with fertility must take effective contraceptive measures. Do not breastfeed.
  13. Male patients must agree to use appropriate contraceptive measures.

排除标准:Exclusion Criteria:

  1. Known or suspected to be allergic to the drug or any component of the drug related to the test;
  2. Patients who can receive targeted treatment;
  3. Other malignant tumors in five years before enrollment, excluding the cured cervical carcinoma in situ, the cured skin basal cell carcinoma, and other types of tumors that were cured only after surgical treatment;
  4. Myocardial infarction, unstable angina pectoris and grade II congestive heart failure in six months before enrollment; New angina pectoris occurred within 3 months; Ventricular arrhythmia requiring medication;
  5. Uncontrolled hypertension after treatment with antihypertensive drugs, i.e. systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg;
  6. History of HIV infection, active period of HCV infection, active period of HBV infection (HBV-DNA>1000 copies/ml);
  7. The researcher judged that there was a risk of bleeding;
  8. Active severe clinical infection (≥ grade 3 CTCAE V5.0);
  9. Epilepsy patients who need medication;
  10. Allogeneic organ transplantation;
  11. Patients who need kidney dialysis;
  12. Thrombotic or embolic venous or arterial events occurred within six months before enrollment;
  13. Serious uncured wounds, ulcers or fractures;
  14. Interstitial pneumonia;
  15. Any malabsorption disease;
  16. Any disease that is unstable or may endanger the patient's safety;
  17. Drug abuse, medical, psychological or social diseases;
  18. Participate in other clinical studies within 3 months before enrollment;
  19. During pregnancy or lactation;

引自 ClinicalTrials.gov, NCT05825443, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05825443,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05825443